<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02116465</url>
  </required_header>
  <id_info>
    <org_study_id>LCD-018/K</org_study_id>
    <secondary_id>2013-003175-35</secondary_id>
    <nct_id>NCT02116465</nct_id>
  </id_info>
  <brief_title>Pharmacokinetic Study With Levodopa-carbidopa Fixed-dose Products in Healthy Subjects After Oral Administration</brief_title>
  <acronym>LCD18K</acronym>
  <official_title>Open-label, Two-treatment, 4-period Replicated Crossover Study in Healthy Subjects to Investigate the Plasma Pharmacokinetics of Levodopa and Carbidopa After Oral Administration of Single Doses of Two Fixed-dose Combination Products</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Desitin Arzneimittel GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Desitin Arzneimittel GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is carried-out to describe and compare the plasma pharmacokinetics of levodopa and
      carbidopa after oral single-dose administration of 100 mg levodopa plus 25 mg carbidopa by
      means two fixed combination products (test: Isicom® 100/25 mg; reference: Nacom® 100/25 mg).

      Additionally, to describe and compare the safety and tolerability of the two investigational
      treatments administered to healthy subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Isicom® 100/25 mg and Sinemet® (Trade name in Germany: Nacom®) 100/25 mg are authorised
      fixed-combination products containing 100 mg levodopa plus 25 mg carbidopa. These two
      formulations were tested for bioequivalence in 1997 (DESITIN trial № LCD-010/K); based on the
      regulatory provisions in place at that time (CPMP/EWP/QWP/1401/98), the two formulations
      could be accepted to be bioequivalent.

      The present study is proposed to be conducted in order to verify and confirm the
      bioequivalence of Isicom® 100/25 mg (test formulation) and Nacom® 100/25 mg (reference
      formulation) in agreement with the pertinent regulatory guidance that came in place 2010
      (CHMP Guideline On The Investigation Of Bioequivalence - CPMP/EWP/QWP/1401/98- Rev. 1/ Corr -
      Jan.2010).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax and AUC(0-tz) of levodopa and carbidopa</measure>
    <time_frame>12 hours</time_frame>
    <description>Cmax (maximal plasma concentration), AUC (area under the curve)</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Fasted State</condition>
  <arm_group>
    <arm_group_label>Levodopa Carbidopa 100/25 tablets Test 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral dose of levodopa carbidopa immediate release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa Carbidopa 100/25 tablets Ref. 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral dose of levodopa carbidopa immediate release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa Carbidopa 100/25 tablets Test 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral dose of levodopa carbidopa immediate release tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levodopa Carbidopa 100/25 tablets Ref. 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>single oral dose of levodopa carbidopa immediate release tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levodopa Carbidopa immediate release tablets</intervention_name>
    <description>oral administration</description>
    <arm_group_label>Levodopa Carbidopa 100/25 tablets Test 1</arm_group_label>
    <arm_group_label>Levodopa Carbidopa 100/25 tablets Ref. 1</arm_group_label>
    <arm_group_label>Levodopa Carbidopa 100/25 tablets Test 2</arm_group_label>
    <arm_group_label>Levodopa Carbidopa 100/25 tablets Ref. 2</arm_group_label>
    <other_name>isicom 100/25 mg</other_name>
    <other_name>Nacom 100/25 mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males or females (females of non-childbearing potential or of childbearing potential
             while taking medically appropriate contraception)

          -  Race: Caucasian

          -  Age: 18 to 45 years

          -  Body weight: 50 100 kg

          -  Body Mass Index: 18 26 kg.m-2

          -  Healthy based on the screening examination

          -  Willing and able to provide informed consent

        Exclusion Criteria:

          -  Previous participation in this trial or participant in any other trial during the last
             90 days

          -  Donation of blood or plasma during the last 90 days or a history of blood loss
             exceeding 300 mL within the last 3 months

          -  History of any clinically relevant allergy including hypersensitivity to levodopa or
             carbi-dopa and related excipients

          -  Presence of any acute or chronic infection

          -  Presence or history of any relevant co-morbidity

          -  Resting systolic blood pressure &gt; 160 or &lt; 90 mmHg, diastolic blood pressure &gt; 95 or &lt;
             50 mmHg

          -  Clinically relevant ECG-abnormalities, in particular prolonged QTc(F) of &gt; 450 msec in
             males and &gt; 460 msec in females

          -  Presence of any relevant abnormality in the laboratory safety tests, especially low
             haemo-globin (&lt; 120 g/L in females and (&lt; 136 g/L in males) and increased liver
             enzymes (2 times the upper limit of the normal range)

          -  Positive serology for HBsAg or anti HCV

          -  Positive HIV test

          -  Positive alcohol or urine drug test at screening

          -  Regular use of any prescription medicine (except for contraceptives) or
             over-the-counter product, herbal product, hormone supplement, etc. in the 30 days
             prior to the Screening visit

          -  History of alcohol and/or drug abuse and/or daily use of &gt; 30 g alcohol

          -  Smoking more than 10 cigarettes/day or equivalent of other tobacco products

          -  Suspicion or evidence that the subject is not trustworthy and reliable

          -  Suspicion or evidence that the subject is not able to make a free consent or to
             understand the information in this regard.

          -  Positive pregnancy test

          -  Lactating

          -  Female subjects of child-bearing potential not using appropriate contraception in the
             3 weeks prior to enrolment until two weeks after the last dose of the trial medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Clinical Pharmacology</name>
      <address>
        <city>Sofia</city>
        <zip>1527</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2014</study_first_submitted>
  <study_first_submitted_qc>April 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2014</study_first_posted>
  <last_update_submitted>April 14, 2014</last_update_submitted>
  <last_update_submitted_qc>April 14, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 17, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levodopa</mesh_term>
    <mesh_term>Carbidopa</mesh_term>
    <mesh_term>Carbidopa, levodopa drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

